OR WAIT null SECS
Urologix, Inc., has received FDA approval to market its CoolWavecontrol unit for use with its catheter-based treatments that usemicrowave technology to treat BPH.
Urologix, Inc., has received FDA approval to market its CoolWave control unit for use with its catheter-based treatments that use microwave technology to treat BPH.
The product’s new user interface and increased processing power will allow urologists to set customized treatments for BPH patients, including those with small glands and symptomatic BPH, the company said. CoolWave will support Urologix’ current Cooled ThermoCath and Targis catheter lines, as well as serve as a platform for future product introductions and technologies, such as the thermal imaging technology under development with ProUroCare, Inc. and Rensselaer Polytechnic Institute.
CoolWave will be previewed at the upcoming AUA annual meeting in Atlanta and is expected to launched in 2007.